CAR T-CELL THERAPY

 

CAR T-cell therapy is a form of immunotherapy that uses specially modified T-cells — part of the immune system — to fight various diseases: cardiovascular, cancer and even age! A sample of a patient’s T cells is taken from the blood, then modified to produce special structures called chimeric antigen receptors (CARs) on their surface.

 

We develop, conduct clinical trials and introduce into the clinic new methods of cancer therapy using cellular (CAR-T) therapy with trogocytosis.

Tumor factors stimulate trogocytosis, a process derived from the Greek word trogo, which means to gnaw or chew. When T cells interact with cancer cells, they can sometimes bite off part of the cancer cell’s membrane. When this membrane segment includes an antigen, a cancer-specific molecule, T cells can then begin to express that antigen on their own cell surface, making it look like a cancer cell to other T cells.

ATF3 gene, opposes CH25H activity. Elimination of AFT3 prevents the occurrence of trogocytosis and restores the ability of T cells to kill tumor cells. Since trogocytosis may reduce the efficiency of engineered T cells delivered to CAR T, blocking it may improve the efficiency of CAR T. Delivery of CAR T cells enriched in CH25H improves the survival of animal models with cancer compared to unarmored CAR T cells. www.cell.com/cell-metabolism/fulltext/S1550-4131(22)00350-3

Recently, CAR-T therapy has been considered as a targeted therapy for aging.

www.nature.com/articles/s41586-020-2403-9

We are developing new therapy strategies. age-related diseases, including the cardiovascular system. doi.org/10.1016/j.arr.2020.101072